The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma

S Dutta*1, JJ Going2, ABC Crumley1, Z Mohammed1, C Orange3, J Edwards3, GM Fullarton1, PG Horgan1 and DC McMillan1

1University Department of Surgery, Faculty of Medicine, University of Glasgow, Royal Infirmary, Glasgow, UK; 2Department of Pathology, Glasgow Royal Infirmary, Glasgow, UK; 3Unit of Experimental Therapeutics, Department of Surgery, Institute of Cancer, College of MVLS University of Glasgow, Western Infirmary, Glasgow, UK

Oesophageal cancer is the sixth most common cause of cancer death in United Kingdom (Cancer Research UK Information Resource Centre, 2006). Overall survival from oesophageal cancer remains poor even after potentially curative surgery, with or without neo-adjuvant therapy (Lerut et al, 2004; Courrech Staal et al, 2010).

It is increasingly recognised that outcomes for patients with cancer are determined by host as well as tumour-related factors. Host-related factors include local and systemic inflammatory responses (Colotta et al, 2009; McMillan, 2009; Roxburgh and McMillan, 2010; Hanahan and Weinberg, 2011) and an increased systemic inflammatory response before surgery is an independent prognostic factor of survival following resection of oesophageal cancer (Nozoe et al, 2001; Ikeda et al, 2003; Shimada et al, 2003; Gockel et al, 2006). For example, on a comprehensive examination of the prognostic value of both tumour- and patient-related factors, only modified Glasgow Prognostic score (mGPS) and positive to total lymph node ratio (LNR) were independent predictor of cancer-specific survival in oesophageal cancer (Dutta et al, 2011).

With reference to the local inflammatory response, a pronounced tumour inflammatory cell infiltrate of gastro-oesophageal carcinomas (assessed on haematoxylin and eosin-stained sections) has been reported to be associated with improved survival (Ma et al, 1994). It is of interest therefore, that Klintrup et al (2005) reported a simplified subjective assessment of the inflammatory infiltrate at the invasive margin of colorectal cancer, including all inflammatory cell types and classifying the infiltrate...
as low or high grade, had independent prognostic value. This method, in addition to being validated in an independent cohort of colorectal cancer patients (Roxburgh et al, 2009a, 2009b), has also been validated in patients with gastro-oesophageal cancer (Crumley et al, 2011).

More specifically, CD8+ T-lymphocytes have been reported to provide prognostic information in oesophageal cancer (Schumacher et al, 2001; Cho et al, 2003). Also, tumour-associated macrophages (CD68+) may have prognostic value in oesophageal cancer (Koide et al, 2002; Guo et al, 2007). Therefore, it would appear that the type, density and location of tumour inflammatory cells are important in determining cancer outcome in these patients. However, to date the few reports, for example, Crumley et al (2011) have been in heterogeneous cohorts of patients including oesophageal, junctional, and gastric sites and squamous and adenocarcinomas. Therefore, the prognostic value of measures of the local inflammatory response in patients with oesophageal cancer, in particular in adenocarcinoma, remains to be established.

The basis of the relationship between the tumour and local and systemic inflammatory responses and outcome is not clear. However, a plausible hypothesis is that rapidly proliferating tumours outgrow their blood supply becoming hypoxic and necrotic thereby stimulating both local and systemic inflammatory responses and angiogenesis that, in turn, promote tumour progression and metastases (Vakkila and Lotze, 2004; Degenhardt et al, 2006). Indeed, it has been reported that high tumour proliferative activity is associated with poorer survival in oesophageal squamous cell cancer. Finally, consistent with the above hypothesis is the report that tumour proliferative activity was associated with tumour angiogenesis in oesophageal squamous cell cancer (Imdahl et al, 2000). Also, Elpek et al (2001) have reported that CD34+ -positive intra-tumoural microvessel density was associated with poorer survival in oesophageal squamous cell cancer. Therefore, consistent with the above hypothesis is the report that tumour proliferative activity was associated with tumour angiogenesis in oesophageal squamous cell cancer.

Although histological evidence of tumour necrosis is recognised to be associated with decreased survival in other gastrointestinal malignancies such as pancreas and colorectal (Hiraoka et al, 2010; Pollheimer et al, 2010; Richards et al, 2011). To our knowledge, the prognostic value of value of tumour necrosis in patients with oesophageal cancer, either squamous or adenocarcinoma, has not been previously reported.

The aim of this study was to examine the relationship between tumour necrosis, tumour proliferation, local and systemic inflammatory responses and microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma.

PATIENTS AND METHODS

A total of 121 patients undergoing potentially curative resection for oesophageal carcinoma at Glasgow Royal Infirmary between January 1996 and May 2009 were included.

Carcinomas were staged according to the tumour node metastasis (TNM) criteria, sixth edition of the International Union Against Cancer (UICC) Classification (Sobin and Wittekind, 2002). Tumours of the gastro-oesophageal junction were further subdivided by site, using the Siewert classification; type I and II lesions of the gastro-oesophageal junction were designated oesophageal cancers and included in this study, while type III tumours of the cardia were designated gastric cancer and therefore excluded (Siewert and Stein, 1996). Only TNM stage I–III tumours were considered amenable to curative surgical resection and included in the study.

All patients underwent potentially curative en-bloc lymphadenectomy and survived at least 30 days following surgery. In all, 47 patients received neo-adjuvant chemotherapy, mostly in last 3 years of the study period. Oesophageal cancer patients and type I gastro-oesophageal junctional tumour received two cycles of preoperative cisplatin and 5-flurouracil as in the MRC OE-O2 study (Medical Research Council Oesophageal Cancer Working Group, 2002). Type II gastro-oesophageal junctional tumour was treated with three cycles of ECF (epirubicin, cisplatin and 5-flurouracil).

This study was approved by the Research Ethics Committee of Glasgow Royal Infirmary.

Biochemical measurements

The coefficient of variation for laboratory measurements of albumin and C-reactive protein, over the range of measurement, was <10% as established by laboratory quality control procedures. The limit of detection of the assay was a C-reactive protein concentration <6 mg l^{-1}. A C-reactive protein concentration >10 mg l^{-1} was considered to indicate the presence of a systemic inflammatory response (McMillan et al, 2001).

The mGPS was constructed as previously described (McMillan, 2008). An elevated C-reactive protein (>10 mg l^{-1}) was assigned a mGPS of 1 or 2 depending on the absence or presence of hypoalbuminaemia (<35 g l^{-1}). Patients in whom neither abnormality was present were allocated an mGPS score 0.

Assessment of tumour necrosis

The same routine haematoxylin and eosin slides from the resected tumour specimens were used to evaluate tumour necrosis over the entire area of invasive carcinoma available. The scoring method for evaluating necrosis was adapted from a previously published protocol (Ikpatt et al, 2002) where it was subjectively graded into three categories using complete haematoxylin and eosin-stained histological sections. Score 0, absent: no confluent necrosis at all, that is, only single-cell death (apoptosis) identifiable. Score 1, mild: confluent areas of invasive carcinoma cell necrosis in <25% of ×40 fields. Score 2, moderate: confluent areas of invasive carcinoma cell necrosis in 25–50% of ×40 fields. Score 3, extensive: confluent areas of invasive carcinoma cell necrosis in >50% of ×40 fields. These scores were aggregated as low grade (scores 0 and 1) or high grade (scores 2 and 3) (Figure 1A and B, respectively). Confluent necrosis was defined as areas of definite death of small or large foci of carcinoma cells with some or all of the following features: condensation, darker staining, fragmentation or total loss of tumour cell nuclei; increased cytoplasmic eosinophilia, loss of cytological detail, granular eosinophilic debris, occasionally with calcification. All cases were scored independently by two observers (SD, JG) blinded to clinical outcomes. In case of disagreement in the score, an agreed score was determined by revision of the specimen by both of the observers together in a double-headed microscope.

Assessment of tumour inflammatory infiltrate

The routine haematoxylin and eosin slides from the resected tumour specimens were retrieved from the pathology archive and scored as described by Klintrup et al (2005). Tumours were scored based on the appearance at the deepest area of tumour invasion on a four-point score. A score of 0 indicated that there was no increase in the inflammatory cells at the deepest point of the tumours invasive margin; score 1 denoted a mild and patchy increase in the inflammatory cells; score 2 denoted a prominent inflammatory reaction forming a continuous band at the invasive margin with some evidence of destruction of cancer cell islands and score 3 denoted a florid ‘cup-like’ inflammatory infiltrate at the invasive edge with frequent destruction of cancer cell islands. These scores were then subsequently classified as low grade (scores 0 and 1) or high grade (scores 2 and 3) (Figure 2A and B, respectively). All cases were scored independently by two
observers (SD or AC and JG). Observers were blinded to the clinical outcome of the patient. The inter-observer intraclass correlation coefficient for tumour inflammatory infiltrate was 0.81.

Tissue micro array (TMA) construction

The routine haematoxylin and eosin slides of the resected tumour specimens along with corresponding paraffin blocks were retrieved from the pathology archive for all patients in our study group. A minimum of three representative areas of tumour were defined by the researcher (SD) and the pathologist (JG). Tissue micro arrays were then constructed in triplicate cores 0.6-mm in diameter from each tumour, which were placed in separate TMA blocks (Beecher Scientific, Silver Spring, MD, USA) as previously described (Kononen et al, 1998). Sections 2.5 μm thick from each TMA block were mounted on silanised glass slides. These sections were used to perform immunohistochemistry for CD8+ T cells, CD68+ (tumour-associated macrophages), Ki-67 (tumour proliferative index) and CD34+ (for microvessel density) (Figures 3A to D, respectively). This was performed in the Unit of Experimental Therapeutics, Institute of Cancer, College of MVLS University of Glasgow, Western Infirmary, Glasgow, UK.

Immunohistochemistry

Immunohistochemistry of TMA slides was performed using the Dako Envision method (Dako, Cambridgeshire, UK). The primary antibody for CD8+ was monoclonal mouse anti-human CD8+, clone CD8+/144B (DAKO, Glostrup, Denmark) at a dilution of 1:100 (overnight incubation) and for CD68+ was monoclonal mouse anti-human CD68+, clone PG-M1 (DAKO) at a dilution of 1:200 (1-h incubation). The primary antibody for Ki-67 was monoclonal mouse anti-human Ki-67, clone MIB-1(DAKO) at a dilution of 1:50 (overnight incubation) and for CD34+ was monoclonal mouse anti-human, CD34+ class II, clone QBEnd 10 (DAKO) at a dilution of 1:150 (30-min incubation).

Cores were dewaxed and rehydrated. Antigen retrieval was performed by keeping the slides in Tris EDTA buffer (pH 8), in pressure cooker for 5 min. Endogenous peroxidise was blocked by incubation in 3% hydrogen peroxide for 10 min. The cores were then incubated with the normal horse serum at dilution 1:20 for 20 min at 25°C to block nonspecific binding sites. Respectively primary antibody was added in appropriate concentrations. Sites of binding were detected using the Envision technique (DAKO code K5007) with DAB (3,3'-diaminobenzidine, Vector code SK 4001, Burlingame, CA, USA), a chromogenic substrate, according to the
Morphometry

For automated image analysis of digitised slides were accessed through the Slidepath Image Analysis system (Leica Microsystems GmbH, Wetzlar, Germany) and evaluated with the program’s nuclear (for Ki-67), cytoplasmic (for CD68+) and membranous (for CD8+) scoring algorithm.

Individual TMA cores were identified, annotated on the scanned image and associated with TMA map entries. Individual nuclei stained with haematoxylin and/or polymerised diaminobenzidine are identified by a thresholding and segmentation algorithm, which outlines nuclei and separates touching nuclei. Nuclear size (area) limits can be specified to accept or reject individual nuclei to be quantified. Staining for Ki-67 in each nucleus was classified as positive or negative based on the threshold specified by the observer. Pseudo-colours (red/orange/yellow/blue) display these staining intensity measurements for individual nuclei, allowing thresholds to be chosen appropriately. These thresholds were chosen using a sample of TMA cores from the whole cohort and once chosen were used for analysis over the entire patient cohort without further adjustment.

For CD68+, +, intracellular and positive pixel detection algorithm was used and for the CD8+, algorithm for thin cell membrane was used. Each TMA cores were crosschecked by one of the investigators (SD) to detect any obvious error. Moreover, at least 25% of the cases were counted by a second observer (ZM) and interclass correlation coefficient for CD34+ (SD) and at least 25% of the cases were counted by a second observer (ZM) and interclass correlation coefficient for CD34+ was 0.83.

Statistical analysis

Survival analysis of the group variables was performed using the Cox proportional hazard model including deaths up to the end of May 2011. Multivariate survival analysis, including all covariates were omission of the primary antibody.

**Table 1** Clinico-pathological characteristic of patients undergoing potentially curative resection for oesophageal cancer (n = 121)

| Patient-related factors | Adeno (n = 98) | Squamous (n = 23) | P-value |
|-------------------------|----------------|------------------|---------|
| Age ( < 65/65–74/ ≥ 75 years) | 57/35/6 | 15/6/2 | 0.755 |
| Sex (male/female) | 83/15 | 10/13 | <0.001 |
| mGPS (0/1/2) | 87/9/2 | 18/5/0 | 0.362 |
| Klintrup–Mäkinen score | 77/21 | 17/6 | 0.591 |
| CD34+ tertiles (1/2/3) | 25/39/34 | 17/5/1 | <0.001 |
| CD68+ tertiles (1/2/3) | 25/35/38 | 12/9/2 | 0.002 |
| Tumour-related factors | | | |
| TNM stage (IV/II/III) | 15/33/50 | 7/11/5 | 0.011 |
| Tumour differentiation (well-mod/poor) | 60/38 | 11/12 | 0.251 |
| Resection margin (R0/R1) | 75/23 | 20/3 | 0.399 |
| LNR (0/1 ≤ 0.2/ > 0.2) | 35/35/28 | 11/4/3 | 0.132 |
| Necrosis score (low grade/high grade) | 48/50 | 9/14 | 0.488 |
| CD34+ tertiles (1/2/3) | 34/29/35 | 5/8/10 | 0.488 |
| CD68+ tertiles (1/2/3) | 26/33/39 | 15/8/0 | <0.001 |
| Neo-adjuvant therapy (no/yes) | 53/45 | 21/2 | 0.001 |
| Adjuvant therapy (no/yes) | 81/17 | 22/1 | 0.191 |
| Alive | 45 | 8 | |
| Cancer-specific death | 49 | 11 | |
| Non-cancer death | 4 | 4 | 0.893* |

**Abbreviations:** LNR = lymph node ratio; mGPS = modified Glasgow Prognostic score; TNM = tumour node metastasis. *Log rank test (Mantel–Cox).

with a P-value of ≤0.1 was performed using a stepwise backward procedure to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding P-value had to be > 0.05. The relationships between the mGPS and other variables were analysed using the Mantel–Haenszel (χ²) test for trend as appropriate. Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).

**RESULTS**

A total of 121 patients with oesophageal cancer were included in our study (Table 1). Overall, the majority of patients were male (81%), < 65 years of age (60%) and had an mGPS of 0 (87%). Most of the patients had pTNM stage II or III (82%), adenocarcinoma...
(81%), well to moderately differentiated tumour (59%), no resection margin involvement (79%), lymph node involvement (72%) and had high-grade tumour necrosis (53%). In all, 27 patients had high-grade peri-tumour inflammatory infiltrate according to Klintrup–Makinen criteria (22%). The median values for CD8 +, CD68 + and Ki-67 were 4.7%, 14.5% and 20.3%, respectively, and for CD34 + the median value was 40. The majority did not receive either neo-adjuvant (61%) or adjuvant (85%) therapy.

The relationship between tumour type (adenocarcinomas) and clinic-pathological characteristics are shown in Table 1. Patients with oesophageal adenocarcinoma were more likely to be male (P < 0.001), had higher infiltration of CD8 + (P < 0.001) and CD68 + (P < 0.01), had higher TNM stage (P < 0.05), had neo-adjuvant therapy (P < 0.01), and as well as had higher CD34 + positive microvessel compared with squamous cell carcinoma (P < 0.001, Table 1). There was no significant difference in the degree of tumour necrosis.

Owing to the limited number of patients with squamous cancer the relationship between clinic-pathological factors and cancer-specific survival was examined only in those patients with oesophageal adenocarcinomas (n = 98, Tables 2). In patients with oesophageal adenocarcinoma, the median follow-up of survivors was 45 months with a minimum of 22 months. During this period, 49 (50%) patients died of their cancer and 4 (4%) patients died of non-cancer causes. In patients with oesophageal squamous cell carcinoma, median follow-up of survivors was 90 months with a minimum of 23 months. During this period, 11 (48%) patients died of their cancer and 4 (17%) patients died of non-cancer causes.

On univariate analysis, only age (P < 0.05), mGPS (P < 0.01), TNM stage (P < 0.001), tumour differentiation (P < 0.001), resection margin (P < 0.10), LNR (P < 0.001), Klintrup–Makinen score (P < 0.05), CD8 + (P < 0.05), CD68 + (P < 0.10) and Ki-67 (P < 0.05) were significantly associated with cancer-specific survival. On multivariate analysis, age (HR 1.93, 95% CI 1.23–3.04, P = 0.004), mGPS (HR 2.91, 95% CI 1.51–5.62, P = 0.001), LNR (HR 2.38, 95% CI 1.60–3.52, P < 0.001) and CD68 + (HR 1.49, 95% CI 1.02–2.18, P = 0.041, Figure 4) retained independent significance (Table 2).

Interrelationships between clinical and pathological characteristics are shown in Table 3. Male sex was associated with poor tumour differentiation (P < 0.01). Tumour node metastasis stage was directly associated with poor tumour differentiation (P < 0.01), positive resection margin (R1) (P < 0.001) and LNR (P < 0.001). Poorly differentiated oesophageal adenocarcinoma was directly associated with a LNR (P < 0.001), inversely with the necrosis score (P < 0.05) and directly with CD68 + infiltration (P < 0.05). Positive resection margin (R1) was directly associated with a LNR (P < 0.01) and inversely with CD8 + infiltration (P < 0.01). A LNR was directly associated with the Klintrup–Makinen score (P < 0.01). The Klintrup–Makinen score was directly associated with CD8 + infiltration (P < 0.01). Tumour necrosis was not significantly associated with any tumour measure other than the degree of differentiation. Tumour CD8 + infiltration was directly associated with CD68 + infiltration (P < 0.01), CD34 + (P < 0.05) and neo-adjuvant therapy (P < 0.05). Tumour CD8 + infiltration of the oesophageal adenocarcinoma was directly associated with the Ki-67 proliferation index (P < 0.001) as well as neo-adjuvant therapy (P < 0.01).
therapy ($P<0.01$). The tumour Ki-67 proliferation index was directly associated with CD34 + microvessel density ($P=0.05$) and neo-adjuvant therapy ($P<0.001$).

Interrelationships between clinical and pathological characteristics of patients who did not receive neo-adjuvant chemotherapy in oesophageal adenocarcinoma are shown in Table 4 ($n=53$). Tumour node metastasis stage was directly associated with poor tumour differentiation ($P<0.05$), positive resection margin (R1) ($P=0.001$) and LNR ($P<0.001$). Poorly differentiated oesophageal adenocarcinoma was directly associated with a LNR ($P=0.001$) and directly with CD68 + infiltration ($P<0.05$). Positive resection margin (R1) was directly associated with a LNR ($P<0.05$) and inversely with CD8 + infiltration ($P<0.05$). A LNR was directly associated with the Klintrup–Makinen score ($P<0.01$) and inversely with CD8 + infiltration ($P<0.05$). The Klintrup–Makinen score was directly associated with CD8 + infiltration ($P<0.05$).

The relationship between clinic-pathological factors and cancer-specific survival was examined also in a subgroup of oesophageal adenocarcinoma patients who did not receive neo-adjuvant therapy ($n=53$, Tables 5). On univariate analysis, only age ($P<0.05$), mGPS ($P=0.001$), TNM stage ($P<0.01$), tumour differentiation ($P<0.05$), resection margin ($P<0.05$), LNR ($P=0.001$), Klintrup–Makinen score ($P<0.05$) and CD68 + ($P<0.10$) were significantly associated with cancer-specific survival. On multivariate analysis, age (HR 2.62, 95% CI 1.27–5.39, $P=0.009$), mGPS (HR 12.71, 95% CI 4.15–38.94, $P<0.001$), LNR (HR 3.18, 95% CI 1.77–5.72, $P<0.001$) and CD68 + (HR 1.88, 95% CI 1.12–3.15, $P=0.017$) retained independent significance (Table 5).

When multivariate survival analysis was carried out in those patients with stage III adenocarcinoma alone ($n=50$), only age (HR 1.90, 95% CI 1.14–3.17, $P=0.014$) and mGPS (HR 2.91, 95% CI 1.12–7.58, $P=0.029$) were independently associated with cancer-specific survival. None of the markers of inflammatory cell infiltrate, including CD68 + were associated with cancer-specific survival.

**DISCUSSION**

The results of this study show that, in patients with oesophageal cancer, the extent of the inflammatory infiltrate and angiogenesis was greater in adenocarcinoma compared with squamous carcinoma. Furthermore, within the adenocarcinoma cohort, although tumour necrosis was not significantly associated with proliferative activity, inflammatory cell infiltrate and angiogenesis, tumour proliferative activity was directly associated with the extent of macrophage infiltration. Also, the generalised inflammatory and cytotoxic T-lymphocyte infiltrate were inversely associated with the LNR and resection margin respectively. Moreover, patients with neo-adjuvant therapy had more intra-tumoural inflammatory cell infiltrate as well as had higher proliferative activity. When the prognostic value of such tissue factors were examined, only the tumour macrophage infiltration retained significance.

**Table 3** Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for oesophageal adenocarcinoma ($n=98$)

| Predictor of oesophageal adenocarcinoma | S Dutta et al |
|----------------------------------------|--------------|
|                                       |             |
|                                       |             |

| Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for oesophageal adenocarcinoma without neo-adjuvant therapy ($n=53$) |             |
|--------------------------------------------------------------------------------|--------------|
| Age in years ($<65/65–74/75$ years) | 0.131 |
| Sex (male/female) | 0.545 |
| mGPS | 0.624 |
| TNM stage | 0.988 |
| LNR | 0.674 |
| LNR | 0.412 |
| LNR | 0.091 |
| LNR | 0.266 |
| LNR | 0.951 |
| LNR | 0.753 |
| LNR | 0.375 |
| LNR | 0.952 |
| LNR | 0.041 |
| LNR | 0.030 |
| LNR | 0.615 |
| LNR | 0.580 |
| LNR | 0.413 |
| LNR | 0.726 |
| LNR | 0.085 |
| LNR | 0.679 |
| LNR | 0.833 |
| LNR | 0.440 |
| LNR | 0.454 |
| LNR | 0.806 |
| LNR | 0.001 |
| LNR | 0.325 |
| LNR | 0.280 |
| LNR | 0.169 |
| LNR | 0.229 |
| LNR | 0.503 |
| LNR | 0.183 |
| LNR | 0.053 |
| LNR | 0.053 |
| LNR | 0.906 |
| LNR | 0.028 |
| LNR | 0.740 |
| LNR | 0.849 |
| LNR | 0.111 |
| LNR | 0.149 |
| LNR | 0.074 |
| LNR | 0.032 |
| LNR | 0.347 |
| LNR | 0.789 |
| LNR | 0.726 |
| LNR | 0.008 |
| LNR | 0.921 |
| LNR | 0.042 |
| LNR | 0.076 |
| LNR | 0.198 |
| LNR | 0.318 |
| LNR | 0.509 |
| LNR | 0.011 |
| LNR | 0.722 |
| LNR | 0.160 |
| LNR | 0.642 |
| LNR | 0.509 |
| LNR | 0.051 |
| LNR | 0.485 |
| LNR | 0.083 |
| LNR | 0.570 |
| LNR | 0.799 |
| LNR | 0.259 |
| LNR | 0.709 |
| LNR | 0.507 |

**Abbreviations:** LNR = lymph node ratio; mGPS = modified Glasgow Prognostic score; TNM = tumour node metastasis.

**Table 4** Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for oesophageal adenocarcinoma without neo-adjuvant therapy ($n=53$)
intra-tumoural macrophage infiltration (CD68$^+$) and microvessel density (CD34$^+$).

With reference to the tissue factors examined, the results of this study are consistent with previous literature. Cho et al (2003) have reported the prognostic value of CD8$^+$ lymphocyte in 122 patients with oesophageal squamous cell carcinoma. Similarly, Tsuchikawa et al (2011) reported the prognostic significance of CD8$^+$ lymphocytes in 98 patients with oesophageal squamous cell carcinoma. In contrast, in another study involving 130 patients with oesophageal adenocarcinoma, CD8$^+$ lymphocyte was not associated with survival (Zingg et al, 2010). Also, that tumour-associated macrophages (CD68$^+$) had prognostic value in oesophageal cancer (Koide et al, 2002; Guo et al, 2007). Indeed, Koide et al (2002) reported, in 56 patients, that the CD68$^+$ macrophage infiltration was associated with tumour progression index (Ki67) and disease progression in oesophageal squamous cell cancer. Also, Guo et al (2007) reported that, 137 patients with oesophageal squamous carcinoma, a high tumour macrophage infiltrate and a low lymphocytic infiltrate were associated with poor outcome. However, that the high tumour macrophage infiltrate had superior prognostic value. In this study, the relationships between tumour necrosis, tumour proliferation, intra-tumoural inflammatory cell infiltrations and microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma was examined. Given that, of the tumour inflammatory cell infiltrate, the macrophages were most closely associated with survival, it would be of interest to examine the phenotype (e.g., M1 or M2) of the macrophages in detail in patients with oesophageal adenocarcinoma.

In the context of the present results, it is also important to acknowledge that, there is some recent evidence that CD68$^+$ can be expressed on non-myeloid cells including carcinomas (Gottfried et al, 2008). Indeed, Gottfried et al (2008) concluded that CD68$^+$ is not a selective macrophage marker but rather a lysosomal protein that is enriched in macrophages. In this study, the morphology of the cell type was clearly considered during the assessment of CD68$^+$ expression and, although unlikely, it is conceivable that the results of this study may have been influenced by expression of CD68 by non-macrophages cells. Further work is required to examine the extent of possible confounding in this study.

Table 5 Relationships between clinico-pathological factors and survival, in patients selected for potentially curative resection for oesophageal adenocarcinoma without neo-adjuvant therapy (n = 53)

| Predictor of oesophageal adenocarcinoma | Univariate analysis | Multivariate analysis |
|----------------------------------------|--------------------|----------------------|
|                                        | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value |
| Age (≤ 65/65 – 74/≥ 75 years)          | 2.07 (1.13 – 3.77) | 0.027 | 2.62 (1.27 – 5.39) | 0.009 |
| Sex (male/female)                      | 0.77 (0.27 – 2.21) | 0.625 |
| mGPS (0/1/2)                           | 4.14 (1.80 – 9.51) | 0.001 | 12.71 (4.15 – 38.94) | <0.001 |
| TUM stage (I/II/III)                   | 2.46 (1.34 – 4.49) | 0.023 | 3.18 (1.77 – 5.72) | <0.001 |
| Tumn differentiation (well-mod/poor)   | 2.35 (1.13 – 4.92) | 0.004 | 0.246 |
| Resection margin (R0/R1)               | 2.13 (1.02 – 4.49) | 0.046 | 0.552 |
| Positive to total lymph node ratio (0/0.2/0.2) | 2.45 (1.55 – 3.89) | <0.001 | 0.607 |
| Adjuvant therapy (no/yes)              | 2.45 (0.83 – 7.22) | 0.105 |
| Klintrup – Makinen score (low/high grade) | 0.28 (0.08 – 0.92) | 0.036 | 0.055 |
| Necrosis score (low/high grade)        | 1.29 (0.61 – 2.70) | 0.505 |
| CD8 tertiles                           | 0.68 (0.43 – 1.10) | 0.117 |
| CD68 tertiles                          | 1.49 (0.97 – 2.28) | 0.066 | 1.88 (1.12 – 3.15) | 0.017 |
| Ki67 tertiles                          | 1.35 (0.78 – 2.35) | 0.289 |
| CD34 tertiles                          | 0.72 (0.45 – 1.20) | 0.214 |

Abbreviations: CI = confidence interval; LNR = lymph node ratio; mGPS = modified Glasgow Prognostic score; TMM = tumour node metastasis.

together, these results would suggest that tumour necrosis does not link local and systemic inflammatory responses but that the tumour inflammatory infiltrate, in particular macrophages, have a role in the control of tumour progression and dissemination in patients with oesophageal adenocarcinoma.

The present report of tumour necrosis in oesophageal adenocarcinoma is to our knowledge unique in the literature and therefore further work is required to establish whether it has prognostic value and relationship with patient- and tumour-related factors in oesophageal cancer. Furthermore, the basis of the differences in the inflammatory cells and microvessel density in squamous and adenocarcinomas is not clear. However, it may reflect more aggressive nature of squamous cell carcinoma (Siewert et al, 2005). Irrespective, the results do emphasise the heterogeneous nature of oesophageal cancer and may have been a significant confounding factor in previous studies.

Given that preoperative neo-adjuvant chemotherapy might influence the some of the clinico-pathological characteristics examined in this study, a subgroup analysis was performed on patients who did not receive neo-adjuvant therapy. Indeed, when compared with those who did not receive neo-adjuvant therapy, the neo-adjuvant therapy group had higher Ki-67 proliferation index ($P<0.001$) and higher densities of both CD8$^+$ T-lymphocytes ($P=0.016$) and CD68$^+$ macrophages ($P=0.004$). In contrast, in the neo-adjuvant therapy group alone, the association between higher Ki-67 proliferation index and densities of both CD8$^+$ T-lymphocytes and CD68$^+$ macrophages was not significant. The basis of this apparent contradiction is not clear, however, it may suggest that neo-adjuvant therapy does influence the relationship between Ki-67 proliferation index and densities of both CD8$^+$ T-lymphocytes and CD68$^+$ macrophages.

The role of Ki67 in oesophageal cancer is also not well established. It has been reported to predict the complete response in oesophageal cancer following chemo-radio therapy (Takeuchi et al, 2003; Ressiot et al, 2008). However, there are some conflicting reports on the predictive value of Ki67 on survival in oesophageal squamous cell cancer (Youssef et al, 1995; Sarbia et al, 1996; Imdahl et al, 2000). In this study, a high proliferation index in oesophageal adenocarcinoma was associated with poor outcome (on univariate survival analysis) and was also associated with
It was of interest therefore, in this study, that CD68+macrophages was strongly associated with CD8+ T lymphocytes and tumour proliferative index (Ki67) in oesophageal adenocarcinoma. Taken together with the other results above, this would suggest that high tumour lymphocytic infiltrate prevents tumour progression and a high tumour macrophage infiltration promotes tumour proliferation. Given that they are both generally increased together it is likely that the balance of these inflammatory cells determines whether there is tumour progression. However, more work is required to be undertaken to better define these relationships in oesophageal adenocarcinoma.

In summary, of the tissue-based factors examined in this study tumour macrophage infiltration appeared to have a central role in the proliferative activity and the coordination of the inflammatory cell infiltrate and was independently associated with poor outcome in patients with oesophageal adenocarcinoma.

REFERENCES

Cancer Research UK Information Resource Centre (2006) http://info.cancerresearchuk.org/cancerstats/mortality/index.htm
Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuki M, Nakakubo Y, Hiroaka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555 – 1559
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073
Courrech Staal EF, Aleman BM, Booth H, van Velthuysen ML, van Tinteren H, van Sandick JW (2010) Systematic review of the benefits and risks of neo-adjuvant chemoradiation for oesophageal cancer. Br J Surg 97(10): 1482 – 1496
Crumley AB, Going JJ, Hilmy M, Dutta S, Tannahill C, McKernan M, Edwards J, Stuart RC, McMillan DC (2011) Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer. Ann Surg Oncol 18(9): 2604 – 2612
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51 – 64
Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC (2011) Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg 35(8): 1861 – 1866
Elpek GO, Gelen T, Aksoy NH, Erdogan A, Dertsiz L, Demircan A, Keles N (2001) The prognostic relevance of angiogenesis and mast cells in esophageal squamous cell carcinoma. J Surg Pathol 25: 940 – 944
Gockel I, Dirksen K, Messow CM, Junginger T (2006) Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma of the esophagus. J Surg Oncol 84(5): 364 – 371
Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Muller A, Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW (2010) Systematic review of the benefits and risks of neo-adjuvant chemoradiation for oesophageal cancer. Br J Surg 97(10): 1482 – 1496
Guo SJ, Lin DM, Li J, Liu RZ, Zhou CX, Wang DM, Ma WB, Zhang YH, Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. J Clin Invest 121(1): 3 – 14
Hiroaka N, Iino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, Yoshida M, Yamada K, Koyama T, Kanai Y (2010) Tumour necrosis is a new promising prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 103: 1057 – 1065
Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238: 197 – 202
Ikpatt O, Ndoma-Egba R, Collan Y (2002) Prognostic Value of necrosis in Nigerian breast cancer. Adv Clin Pathol 6: 31 – 37
Imdahl A, Jenkner J, Ibling C, Ruckauer K, Farthmann EH (2000) Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer? Ann Surg 179: 514 – 520
Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Korttunen TJ, Makinen MJ (2005) Inflammation and prognosis in colorectal cancer. Eur J Cancer 41: 2645 – 2654
Koido N, Nishio A, Hiraguri M, Kishimoto K, Nakamura T, Adachi W, Amano J (2002) Differences and relationships of thymidine phosphorylase expression in tumor-associated macrophages and cancer cells in squamous cell carcinoma of the esophagus. Dis Esophagus 15: 67 – 73
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Srahfli P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844 – 847
Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D, Ectors N (2004) Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 240: 962 – 972; discussion 972 – 974
Li Z, Liu J, Tang F, Liu Y, Waldum HL, Cui G (2008) Expression of non-mast cell histidine decarboxylase in tumor-associated microvessels in human esophageal squamous cell carcinomas. APMIS 116: 1034 – 1042
Ma XC, Hartteri T, Kusima R, Terata N, Kodama M (1994) Expression of HLA-class II antigen in gastric carcinomas. Its relationship to histopathological grade, lymphocyte infiltration and five-year survival rate. Acta Oncol 33: 187 – 190
McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67: 257 – 262
McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223 – 226
McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArldle CS (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41: 64 – 69
Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727 – 1733
Nomiya T, Nemoto K, Miyachi H, Fujimoto K, Takeda K, Ogawa Y, Takai Y, Yamada S (2004) Relationships between radio-sensitivity and micro-vascular density in esophageal-carcinoma: significance of hypoxic fraction. Int J Radiat Oncol Biol Phys 58: 589 – 596
Nozoe T, Saeki H, Sugimachi K (2001) Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182: 197 – 201
Pohlmeier MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P, Langner C (2010) Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol 41: 1749 – 1757
Ressiot E, Dahan L, Liprandi A, Giorgi R, Djourno XB, Padovani L, Alibert S, Ries P, Laquiere A, Laugier R, Thomas P, Seitz JF (2008) Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol 32: 567
Richards CH, Mohamed Z, Qayyum T, Horgan PG, McMillan DC (2011) The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol 7: 1223
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149
Roxburgh CS, Salmon JD, Horgan PG, Oen KA, McMillan DC (2009a) The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg 13(11): 2011 – 2018
Roxburgh CS, Salmon JD, Horgan PG, Oen KA, McMillan DC (2009b) Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 45: 2138
Sarbia M, Bittinger F, Porschen R, Dutkowski M, Willers R, Gabbert HE (1996) The prognostic significance of tumour cell proliferation in squamous cell carcinomas of the oesophagus. Br J Cancer 74: 1012–1016

Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932–3936

Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83: 248

Siewert JR, Stein HJ (1996) Adenocarcinoma of the gastroesophageal junction. Classification, pathology and extent of resection. Dis Esophagus 9: 173–182

Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg 234: 360–367; discussion 368–369

Sobin LH, Wittekind C editors (2002) TNM Classification of Malignant Tumours. John Wiley & Sons: Hoboken, NJ

Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR (2005) Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 242: 566–573; discussion 573–575

Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M (2003) Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 10: 792–800

Tsuchikawa T, Ikeda H, Cho Y, Miyamoto M, Shichinohe T, Hirano S, Kondo S (2011) Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol 164: 50

Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641–648

Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, Watanabe T, Katsura Y, Waniuchi H, Fukushima S (1995) Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 76: 358–366

Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, Went P, Oertli D (2010) Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol 36: 670

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.